Market Size of Global Acute Agitation and Aggression Treatment Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.90 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Acute Agitation & Aggression Treatment Market Analysis
The acute agitation and aggression treatment market is expected to register a CAGR of 4.9% during the forecast period.
The COVID-19 pandemic has impacted the market significantly. The COVID-19 pandemic had few major effects on the global market for acute agitation and aggression treatment market. The pandemic has directly affected the production and demand of agitation and aggression drugs. It has disrupted distribution channels and had a financial impact on firms and financial markets. However, the clinical trials have increased, and numerous studies have been conducted to find the impact of COVID-19 on agitation and aggression. For instance, according to the article 'Predictors of Adolescent Resilience During the COVID-19 Pandemic: Cognitive Reappraisal and Humor' published in November 2021, more anxiety, depressive symptoms, sleep disturbances, and proactive aggression were linked to greater COVID-19 impact. This suggests that due to increasing aggression among the target population, the demand for psychotic drugs or other treatments for the management of agitation and aggression increased during the pandemic. Therefore, owing to the mentioned factors, the COVID -19 pandemic has significantly impacted the studied market.
Factors such as a rise in the geriatric population and an increase in agitation in patients, an increase in focus on creating awareness about agitation and aggression, and ongoing research on the development of novel treatments for agitation are expected to fuel the market growth over the forecast period.
The increase in the geriatric population is expected to be a major contributor to the studied market. According to World Health Organization (WHO) data published in October 2021, between 2015 and 2050, the proportion of the world's population over 60 years is predicted to nearly double from 12% to 22%. In 2050, 80% of older people will be living in low- and middle-income countries. This target population is more prone to getting age-related agitation and anger issues. Additionally, this population accounts for dementia, which triggers aggression among them. Thus, the increase in the number of geriatrics demands for the availability of treatment options. Thereby driving the demand for the market studied.
Moreover, continuous product innovation and developments are major contributors to market growth. For instance, in May 2022, the first patient was dosed in the TRANQUILITY II study of acute treatment for agitation in patients with Alzheimer's disease. The TRANQUILITY II study is led by BioXcel Therapeutics and focuses on BXCL501, an orally dissolving thin film formulation of dexmedetomidine. Thus, the developments in the market are anticipated to boost market growth over the analysis period.
Therefore, due to the factors mentioned above, the studied market is anticipated to witness growth during the forecast period. However, the preference for non-pharmacological interventions and social stigma associated with mental illness is predicted to restrain the growth of the market.
